Table 1.
Studies Characteristics
| Study (Author & Year) | Country | Interventions (sample size) | Outcomes Data Available for Meta-Analysis | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Experimental Group | Control Group | MMEs (total) | MMEs (24h) | Pain Score (24h) |
Pain Score (48h) |
LOS | Time to first Ambulation | Complications | Readmission | ||
| Salvatore A. Parascandola 201724 | The United States | LB (62) | Bupivacaine (51) | √ | √ | ||||||
| Dana A. Dominguez 201825 | The United States | LB (40) | Bupivacaine with lidocaine (40) | √ | √ | √ | √ | ||||
| Thomas M. Kelley Jr 201826 | The United States | LB (21) | Bupivacaine (26) | √ | |||||||
| Molly Rincavage 201927 | The United States | LB (43) | Bupivacaine (53) | √ | √ | ||||||
| Scott G. Louis 201914 | The United States | LB (50) | Bupivacaine (32) | √ | √ | ||||||
| Alessia Pedoto 202128 | The United States | LB (29) | Bupivacaine (31) | √ | |||||||
| Karishma Kodia 202129 | The United States | LB (129) | Bupivacaine (123) | √ | √ | ||||||
| Kian Banks 202215 | The United States | LB (222) | Bupivacaine (34) | √ | √ | √ | √ | √ | |||
| Benny Weksler 202116 | The United States | LB (25) | Bupivacaine (25) | √ | √ | √ | √ | √ | |||
| Sowmyanarayanan Thuppal 202217 | The United States | LB (26) | Bupivacaine (24) | √ | √ | √ | √ | √ | √ | ||
Abbreviations: LB, liposomal bupivacaine; MMEs, morphine milligram equivalents; LOS, length of stay.